Neurocrine Biosciences Inc. (NBIX)
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
Neurocrine Biosciences NASDAQ: NBIX outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the company's efforts to diversify beyond its largest product, INGREZZA.
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Neurocrine Biosciences: 'House Full Of Options'
Neurocrine Biosciences is rated a 'Buy' based on robust cash flows, strong product launches, and a deep, diversified pipeline. Ingrezza anchors NBIX's profitability, with exclusivity until 2038 and projected peak sales of $3.3B, while Crenessity and Vykat XR add growth pillars. Valuation models yield $224/share (DCF) and $167/share (with all research costs), both above recent market prices, highlighting undervaluation.
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
Neurocrine's shares fell 12% in a month as Vykat XR safety concerns mount, but Ingrezza and Crenessity support growth.
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth
Neurocrine expands its portfolio with INGREZZA, CRENESSITY and VYKAT XR growth, while advancing pipeline catalysts and commercial momentum.
